(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 98.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Insmed's revenue in 2026 is $447,022,000.On average, 20 Wall Street analysts forecast INSM's revenue for 2026 to be $284,506,807,646, with the lowest INSM revenue forecast at $188,107,199,658, and the highest INSM revenue forecast at $388,370,987,049. On average, 19 Wall Street analysts forecast INSM's revenue for 2027 to be $505,031,574,592, with the lowest INSM revenue forecast at $301,142,138,228, and the highest INSM revenue forecast at $681,408,733,455.
In 2028, INSM is forecast to generate $753,495,165,977 in revenue, with the lowest revenue forecast at $508,443,950,096 and the highest revenue forecast at $1,126,937,010,196.